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Enhanced Levels of microRNA-125b in Vascular Smooth
Muscle Cells of Diabetic db/db Mice Lead to Increased
Inflammatory Gene Expression by Targeting the Histone
Methyltransferase Suv39h1
Louisa M. Villeneuve, Mitsuo Kato, Marpadga A. Reddy, Mei Wang, Linda Lanting,
and Rama Natarajan
OBJECTIVE—Diabetes remains a major risk factor for vascular
complications that seem to persist even after achieving glycemic
control, possibly due to “metabolic memory.” Using cultured
vascular smooth muscle cells (MVSMC) from type 2 diabetic
db/db mice, we recently showed that decreased promoter occu-
pancy of the chromatin histone H3 lysine-9 methyltransferase
Suv39h1 and the associated repressive epigenetic mark histone
H3 lysine-9 trimethylation (H3K9me3) play key roles in sustained
inﬂammatory gene expression. Here we examined the role of
microRNAs (miRs) in Suv39h1 regulation and function in
MVSMC from diabetic mice.
RESEARCH DESIGN AND METHODS—We used luciferase
assays with Suv39h1 3untranslated region (UTR) reporter con-
structs and Western blotting of endogenous protein to verify that
miR-125b targets Suv39h1. We examined the effects of Suv39h1
targeting on inﬂammatory gene expression by quantitative real
time polymerase chain reaction (RT-qPCR), and H3K9me3 levels
at their promoters by chromatin immunoprecipitation assays.
RESULTS—We observed signiﬁcant upregulation of miR-125b
with parallel downregulation of Suv39h1 protein (predicted
miR-125b target) in MVSMC cultured from diabetic db/db mice
relative to control db/. miR-125b mimics inhibited both
Suv39h1 3UTR luciferase reporter activity and endogenous
Suv39h1 protein levels. Conversely, miR-125b inhibitors showed
opposite effects. Furthermore, miR-125b mimics increased ex-
pression of inﬂammatory genes, monocyte chemoattractant pro-
tein-1, and interleukin-6, and reduced H3K9me3 at their
promoters in nondiabetic cells. Interestingly, miR-125b mimics
increased monocyte binding to db/ MVSMC toward that in
db/db MVSMC, further imitating the proinﬂammatory diabetic
phenotype. In addition, we found that the increase in miR-125b in
db/db VSMC is caused by increased transcription of miR-125b-2.
CONCLUSIONS—These results demonstrate a novel upstream
role for miR-125b in the epigenetic regulation of inﬂammatory
genes in MVSMC of db/db mice through downregulation of
Suv39h1.Diabetes 59:2904–2915, 2010
D
iabetes is associated with increased risk for
cardiovascular complications related to vascu-
lar inﬂammation and atherosclerosis (1–2). Hy-
perglycemia has been implicated in several
diabetic complications via the activation of key signaling
pathways leading to inﬂammatory gene expression (2–10).
Increased levels of inﬂammatory cytokines and chemo-
kines such as interleukin-6 (IL-6) and monocyte chemoat-
tractant protein-1 (MCP-1) have been associated with
diabetic complications and insulin resistance (2,4,10).
Chronic inﬂammation and lipid accumulation in the arte-
rial walls lead to monocyte/macrophage recruitment as
well as vascular smooth muscle cell (VSMC) migration and
proliferation to promote atherosclerosis (1,11), and these
events are further accelerated in diabetes. Although it is
known that inﬂammatory genes play key roles in the
progression of atherosclerosis and diabetic complications,
much less is known about the mechanism of their regula-
tion especially at the level of chromatin or microRNAs.
Gene expression is regulated by active and repressed
states of chromatin which rely not only on transcription
factor binding, but also on the recruitment of protein
complexes that change chromatin structure through epi-
genetic post-translational modiﬁcations of histone tails
such as acetylation, phosphorylation, ubiquitination, and
methylation. Furthermore, histone lysine (K) residues can
be mono-(me1), di-(me2), or tri-(me3) methylated at vari-
ous positions depending on the speciﬁcity of the histone
methyl transferase (HMT) (12). Histone H3K9me3 can be
mediated by the mammalian homologs of the Drosophila
suppressor of position effect variegation, SUV39H1 in
humans and Suv39h1 in mice, and plays an important role
in heterochromatic silencing (13). Reports also show a
role for SUV39H1 and H3K9me3 in euchromatic transcrip-
tional repression (14). Changes in H3K9me have also been
identiﬁed at the promoters of inducible inﬂammatory
genes in monocytes and dendritic cells (15–16).
Clinical studies (17–20) have shown that prior conven-
tional versus intensive glycemic control can leave a met-
abolic or transcriptional memory on target cells that lead
to sustained long-term complications even after attain-
ment of normoglycemia. We recently showed that VSMC
cultured from the aortas of type 2 diabetic db/db mice
(cultured vascular smooth muscle cells [MVSMC]) dis-
played a preactivated phenotype with enhanced inﬂamma-
tory gene expression and proatherogenic responses
relative to MVSMC from genetic control db/ mice, even
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ing metabolic memory of sustained vascular dysfunction
in this model (21–22). Further studies showed that epige-
netic chromatin histone lysine methylation on inﬂamma-
tory gene promoters was altered in MVSMC from db/db
mice. Thus, there was decreased repressive histone H3
lysine-9 trimethylation mark (H3K9me3) at the promoters
of upregulated inﬂammatory genes in db/db MVSMC rela-
tive to control db/ (22). Histone lysine methylation at
several loci, including inﬂammatory genes, was also al-
tered in VSMC and monocytes cultured in high glucose
(22–23). Two other reports have implicated histone H3
lysine-4 methylation with increased NF-B and inﬂamma-
tory gene expression and hyperglycemic memory in endo-
thelial cells (24–25). We also demonstrated that Suv39h1
protein occupancy was reduced in parallel with the de-
creased H3K9me3 levels at the promoters of upregulated
inﬂammatory genes in response to an inﬂammatory stim-
ulus in cultured db/db MVSMC relative to db/ cells even
after several passages in vitro, suggesting a potential role
for Suv39h1 dysregulation in this model of metabolic
memory (22). Although this evidence supports a dynamic
role for Suv39h1 and H3K9me3 in inﬂammatory gene
expression, the mechanism of Suv39h1 regulation itself
under these diabetic conditions is unclear and was there-
fore investigated in this study.
MicroRNAs (miRs) pose an exciting emerging area of
research because of their involvement in diverse biologic
processes. The miRs are short noncoding RNAs (21–25
nucleotides in length) that can negatively regulate gene
expression. Most mammalian miRs bind to the 3untrans-
lated regions (UTRs) of target mRNA transcripts leading to
post transcriptional and translational repression, mRNA
cleavage or degradation (26–27). Numerous miRs have
been identiﬁed or predicted; however, their cellular tar-
gets, biologic roles and disease relevance are still under
investigation. miRs have been found to play key roles in
carcinogenesis (28), development, differentiation, fat me-
tabolism, and insulin secretion (26–29). In VSMC, key
miRs such as miR-21, miR-143, miR-145, and miR-221 have
recently been shown to play important roles in phenotypic
changes, migration, proliferation, and neointimal thicken-
ing (30–34). Key miRs such as miR-192, miR-216, and
miR-377 were upregulated in renal cells leading to in-
creased collagen and ﬁbronectin expression associated
with the pathogenesis of diabetic nephropathy (35–38).
Evidence also shows miR targeting of a histone lysine
methyltransferase EZH2 that mediates H3K27me3 in-
volved in skeletal muscle differentiation (39), thereby
suggesting a role for miRs in chromatin remodeling.
In the current study, we evaluated whether miRs might
play a role in the dysregulation of Suv39h1 and associated
chromatin H3K9me3 related to the increased expression of
inﬂammatory genes observed in MVSMC of diabetic db/db
mice (22). We report that, relative to control db mice,
MVSMC cultured from diabetic db/db mice express higher
levels of miR-125b along with key inﬂammatory genes, but
reciprocally express lower levels of the H3K9 HMT
Suv39h1, a target of miR-125b. Downregulation of Suv39h1
by miR-125b led to derepression of key inﬂammatory
chemokines and cytokine genes in nondiabetic cells via
decrease of the repressive H3K9me3 chromatin mark at
their promoters, suggesting that miR-125b can promote a
diabetic phenotype. Thus, we have identiﬁed, for the ﬁrst
time, a miR-dependent mechanism for reduced Suv39h1
and associated epigenetic mechanisms underlying the
increased inﬂammatory gene expression in the MVSMC of
type 2 diabetic mice. These results reveal a previously
uncharacterized miR-chromatin cross-talk mechanism for
inﬂammatory gene expression related to sustained dia-
betic complications.
RESEARCH DESIGN AND METHODS
Materials. Antibodies against H3K9me1 (07-450), H3K9me2 (07-441) and
H3K9me3 (07-442), and SUV39H1 (05-615) were from Millipore (Billerica, MA).
In some experiments (Fig. 1B), SUV39H1 rabbit polyclonal antibody
(ARP32470 T100) from Aviva Systems (San Diego, CA) was used. The -actin
antibody was from Santa Cruz Biotech (Santa Cruz, CA). The SYBR Green
PCR Master Mix kit was from Applied Biosystems (Foster City, CA). RNA-
STAT 60 was from Iso-Tex Diagnostics (Friendswood, TX). The miR-125b
mimic, inhibitors, and negative controls oligonucleotides were from Dharma-
con RNAi Technologies (Lafayette, CO). FLAG-SUV39H1 plasmid vector was
previously described (22). Fluorescent dye 2,7-Bis-(2-carboxyethyl)-5-(and
6)-carboxyﬂuorescein acetoxymethyl ester (BCECF/AM) was from A.G. Sci-
entiﬁc (San Diego, CA).
Cell culture. All animal studies were performed according to protocols
approved by the Institutional Animal Care and Use Committee. Mouse
vascular smooth muscle cells (MVSMC) were isolated from thoracic aortas of
10- to 12-week-old male diabetic (average blood glucose levels 450 mg/dl)
db/db mice (BKS.Cg-m/leprdb/J, Jackson Laboratory, Bar Harbor, ME),
and heterozygous nondiabetic db/ control littermates, as previously de-
scribed (21–22). MVSMC were cultured in Dulbecco’s modiﬁed Eagle’s me-
dium (DMEM)/F12 medium supplemented with 10% FBS for 5 to 8 weeks.
During this period, the db/db cells continued to maintain the diabetic
phenotype relative to db/ cells (21–22). Mouse kidney epithelial cells
TCMK-1 (38) and HeLa (ATCC # CCL2) cells were cultured in DMEM
supplemented with 10% FBS. WEHI78/24 cells (21–22) were cultured in DMEM
containing 10% heat-inactivated FBS.
Immunohistochemistry. Formalin ﬁxed, parafﬁn-embedded sections of db/
and db/db mouse aortas were deparafﬁnized in xylene followed by 100%
ethanol. Quenching in 3% hydrogen peroxide was followed by pretreatment
with steam in DIVA/citrate buffer (pH 6.0) solution to promote antigen
retrieval. Slides were then incubated in Rodent Block-M for 30 min followed
by 30 min with SUV39H1 antibody (1:15) in Dako dilution buffer. Slides were
then washed in Dako wash buffer and incubated for 20 min in MM polymer-
HRP (horseradish peroxidase) followed by incubation with the chromogen
diaminobenzidine tetrahydrochloride (Dako DAB) for 10 min, counterstained
with hematoxylin, and mounted. Images were taken at 40 magniﬁcation
using an Olympus BX51 microscope with InStudio (Pixera Corp) software to
collect images and ImagePro software (Media Cybernetics, MD) to quantify
staining.
Chromatin immunoprecipitation assays. Cells were ﬁxed with 1% formal-
dehyde and chromatin immunoprecipitation (ChIP) assays with cell lysates
using indicated antibodies were performed as previously described (22).
ChIP-enriched DNA samples were analyzed by quantitative polymerase chain
reaction (qPCR) with primers surrounding NF-B binding sites in the indi-
cated gene promoters (data are available in supplemental Table S1, available
online at http://diabetes.diabetesjournals.org/cgi/content/full/db10-0208/DC1),
data analyzed using the 2
-CT method, normalized with input samples, and
results expressed as a percentage of control as described earlier (22).
Western blotting and quantiﬁcation. Immunoblotting was performed as
previously described (40). Brieﬂy, equal amounts of cell lysates were run on
10% denaturing PAGE gels and transferred to nitrocellulose membrane.
Membranes were blocked, incubated with primary antibody, washed, and
incubated with appropriate HRP-conjugated secondary antibody. Membranes
were again washed and protein bands visualized using an enhanced chemilu-
minescence kit (PerkinElmer, Waltham, MA). Contrast was adjusted uni-
formly across the whole autoradiogram to better visualize the bands. Intensity
of protein bands was quantiﬁed using a calibrated densitometer GS-800 and
Quantity One software (Bio-Rad, Hercules, CA).
miR-125b quantiﬁcation. Levels of miR-125b were determined by quantita-
tive real time polymerase chain reaction (RT-qPCR) as described previously
(37,38). Primer sequences are provided in online supplemental Table S1.
Ampliﬁcation of a single fragment was veriﬁed with a single peak in the
dissociation curve, and mean quantity was determined based on a standard
curve ampliﬁed by a known template. As an internal control, 5S RNA
(Ambion) was used (n  3). To conﬁrm results, miScript system was used
with miScript Reverse Transcription Kit and a miScript SYBR Green PCR Kit
(Qiagen, Valencia, CA) for detection of mature miR-125b using primers
speciﬁc for miR-125b according to the manufacturer’s protocols (n  4).
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potential miR-125b target sequence was ampliﬁed by PCR and subcloned
downstream of luciferase gene (in NotI site) of psiCHECK-2 dual luciferase
vector (Promega, WI) in both sense (Suv39h1 S-3UTR) and antisense
(Suv39h1 AS-3UTR) orientations. Primers used for ampliﬁcation were 5-
GGCCCATACAGATTGTCTCAGGGA-3 (sense); and 5-GGCCTCCCTGAGA
CAATCTGTATG-3 (antisense). Similar strategy was used to clone PPAR	
3UTR into psiCHECK-2 vector (sense, 5-GGCCTAAAGAGTTAATT
TCAGGGT-3; AS, 5-GGCCACCCTGAAATTAACTCTTTA-3).
Transfections and luciferase assays. MVSMC were transfected with indi-
cated plasmids/oligos using the Nucleofection method (Lonza) as previously
described (22). TCMK-1 and HeLa cells were transfected using X-tremeGENE
(Roche) according to the manufacturer’s protocols. Transfected cells were
harvested 24–48 h after transfection for various assays as indicated. To
examine the luciferase activity of 3-UTR constructs, TCMK-1 cells were
cotransfected with 10 nmol/l of miR-125b mimic or negative control (NC)
oligonucleotides along with 100 ng of indicated 3-UTR reporter constructs.
MVSMCs were cotransfected with 25 nmol/l of miR-125b mimic or 5 nmol/l of
inhibitor hairpins or the respective negative controls along with 1 
go f
3-UTR reporter constructs. Cells were harvested 48 h after transfection and
luciferase activities in cell lysates determined with the Dual-Luciferase Assay
System (Promega) using TD20/20 luminometer (Turner Designs) or Veritas
microplate luminometer (Turner BioSystems) according to the manufacturer’s
protocols.
RT-qPCR to quantify gene expression. Total RNA was extracted using
RNA-STAT60 and reverse transcription followed by RT-qPCR used to measure
inﬂammatory gene expression levels using -actin as an internal control as
described before (22). Primer sequences are provided in online supplemental
Table S1.
Monocyte binding assays. Monocyte binding assays were performed as
previously described (21) with some modiﬁcations. MVSMC (5  10
5 cells)
were transfected by Nucleofection with indicated oligonucleotides/plasmids
and plated in quadruplicate in 24-well plates. After 48 h, MVSMC monolayers
were incubated with WEHI78/24 mouse monocytic cells (6  10
4/well)
ﬂuorescently labeled with BCECF/AM (10 
g/ml), for 1 h at 37°C. Nonspeciﬁ-
cally-bound monocytes were removed by gently washing monolayers 4 to 5
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FIG. 1. Upregulation of miR-125b, decrease in Suv39h1 expression, and decrease in inﬂammatory gene promoter H3K9me3 levels in diabetic
VMSC. A: The miR-125b levels in cultured MVSMC from db/ and db/db mice were analyzed by RT-qPCR and results expressed as the percentage
of db/ (mean  SEM, **P < 0.01, n  7). B: Quantiﬁcation of Suv39h1 protein levels from MVSMC cell lysates immunoblotted with Suv39h1
antibodies. Results expressed as the percentage of db/ (#, P < 0.001, n  3). C and D: Representative aortic sections from db/ (C) and db/db
(D) mice stained with SUV39H1 antibody (brown) and nuclear stain hematoxylin (blue) (40 magniﬁcation). E: Suv39h1-stained MVSMC nuclei
from (C and D) were counted, and results expressed as the percentage of nuclei stained with Suv39h1 (mean  SE, ***P < 0.0001 vs. db/, n 
3). F: H3K9me3 levels determined by ChIP assays. ChIP enriched DNA samples analyzed by qPCR using indicated promoter (pro) or enhancer
(enh) primers. Results expressed as the percentage of db/ (*P < 0.05; ***P < 0.0001, n  3 for IL-6, and n  4 for MCP-1 promoter and
enhancer). (A high-quality color representation of this ﬁgure is available in the online issue.)
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well) of bound monocytes were taken at 10 magniﬁcation using an Olympus
IX50 microscope and Olympus Microsuite software. The numbers of bound
monocytes were counted using AlphaEaseFC software (Cell Biosciences,
Santa Clara, CA).
Statistics. We used PRISM software (Graph-Pad) for data analysis with
Student t tests or ANOVA. P  0.05 was considered statistically signiﬁcant.
Data are expressed as means  SE.
RESULTS
Upregulation of miR-125b in diabetic db/db mice. To
identify previously uncharacterized roles of miRs in the
increased vascular inﬂammation in diabetes, we screened
for miRs that were differentially expressed in total RNA
obtained from various cells of diabetic db/db versus ge-
netic control db/ mice. Initial miR microarray proﬁling
identiﬁed miR-125b as being upregulated in db/db mice
(unpublished observations). These results were veriﬁed by
RT-qPCR, which revealed a signiﬁcant increase in miR-
125b levels in MVSMC cultured from diabetic db/db mice
relative to control db/ (Fig. 1A). The cultured diabetic
MVSMC also expressed a persistent increase in the expres-
sion of inﬂammatory genes such as MCP-1 and IL-6,a s
previously shown (21–22). Since these MVSMC had been
cultured for several passages outside the diabetic animal,
the sustained increase in miR-125b in the diabetic db/db
cells relative to db/ cells suggests a potential memory of
dysregulated miR-125b expression.
Potential targets of miR-125b. Using computational
miR target predictions from miR databases, including
MIRANDA (http://cbio.mskcc.org), MiRBase Targets
(http://microrna.sanger.ac.uk/targets/v4), and TargetScan
(http://www.targetscan.org/vert_42), we identiﬁed the
3UTR of Suv39h1 as a potential target of miR-125b. The
Suv39h1–3UTR has a perfect match to the miR-125b seed
region and is conserved between human, rat, and mouse
(online supplemental Fig. S1A).
Decreased Suv39h1 expression in diabetic db/db
MVSMC and parallel decrease in H3K9me3 at inﬂam-
matory gene promoters inversely correlates with
miR-125b. We recently demonstrated that reduced
H3K9me3 and recruitment of Suv39h1 at inﬂammatory
gene promoters was a key mechanism underlying the
enhanced inﬂammatory gene expression in db/db
MVSMC (22). We therefore hypothesized that, under
diabetic conditions, upregulation of miR-125b can en-
hance the expression of key inﬂammatory genes by
downregulating its target Suv39h1 with concomitant
reduction in H3K9me3 levels (repressive mark) at the
promoters of these genes associated with vascular
dysfunction. To test this, we next evaluated whether
increased miR-125b inversely correlated with the ex-
pression of its potential target, Suv39h1, in the diabetic
MVSMC. Immunoblotting showed that Suv39h1 protein
levels were decreased by 45% in cultured db/db MVSMC
relative to db/ (Fig. 1B), as also noted previously (22).
Interestingly, immunohistochemistry also revealed a
signiﬁcant decrease in nuclear Suv39h1 protein levels in
MVSMC regions of aortic sections from db/db mice
compared with db/ (Fig. 1C–E), demonstrating in vivo
relevance. Furthermore, ChIP assays showed a signiﬁ-
cant decrease in H3K9me3 levels at the IL-6 and MCP-1
promoters and MCP-1 enhancer in db/db MVSMC rela-
tive to db/ (Fig. 1F). These results demonstrate that
miR-125b levels inversely correlate with Suv39h1 levels,
suggesting a novel mechanistic basis for the decreased
Suv39h1 and reduced H3K9me3 levels associated with
the reciprocal increase in IL-6 and MCP-1 expression in
the db/db MVSMC which persisted even after in vitro
culture for several passages. Interestingly, there were
no changes in global levels of total H3K9me3, H3K9me2,
or H3K9me1 (online supplemental Fig. S2), suggesting
speciﬁcity and that increased miR-125b in db/db cells
affects H3K9me3 only at a subset of gene promoters, but
not total H3K9me3.
Suv39h1 3UTR is a true target of miR-125b. Next, to
verify that the 3UTR of Suv39h1 was indeed an actual
target of miR-125b, we examined the effects of a double-
stranded RNA oligonucleotide mimicking the mature miR-
125b (mimic) on luciferase activity of reporters containing
the Suv39h1 3UTR downstream of luciferase gene in
sense (S-3UTR) or antisense (AS-3UTR) orientations. In
TCMK-1 cells, miR-125b mimic signiﬁcantly decreased
luciferase activity of the Suv39h1 S-3UTR reporter com-
pared with negative control oligonucleotides for the mimic
(NC-M) derived from a C. elegans sequence (Fig. 2A). In
contrast, miR-125b mimic had no effect on either Suv39h1
AS-3UTR or the psiCHECK-2 vector alone (Fig. 2A).
Furthermore, miR-125b did not inhibit the luciferase activ-
ity of a reporter containing the 3-UTR of peroxisome
proliferator activated receptor-	 (PPAR	) which also has
a putative miR-125b binding site (Fig. 2B, and supplemen-
tal Fig. S1B), thus demonstrating speciﬁcity of Suv39h1
3UTR targeting by miR-125b.
Targeting of Suv39h1 3UTR by miR-125b was next
tested in primary MVSMC derived from control db/ mice.
Interestingly, luciferase activity of Suv39h1 S-3UTR trans-
fected with NC-M oligo was decreased relative to empty
psiCHECK-2 vector (control) transfected with NC-M (Fig.
2C), most likely caused by endogenous levels of miR-125b
in db/ cells. Furthermore, luciferase activity of the
S-3UTR (but not control or AS) was further decreased
when cotransfected with miR-125b mimic (Fig. 2C). Since
our data showed that diabetic db/db MVSMC display
higher levels of endogenous miR-125b compared with
db/, we next examined the activity of Suv39h1 S-3UTR
construct in both db/ and db/db MVSMC cells. Results
showed that Suv39h1 S-3UTR activity was signiﬁcantly
lower in db/db MVSMC compared with db/, demonstrat-
ing that higher endogenous miR-125b in db/db cells can
result in enhanced targeting (Fig. 2D).
We next tested whether, reciprocally, an inhibitor of
miR-125b could reverse these effects. We used two hairpin
inhibitors designed to interfere with miR incorporation
into the RISC complex, thereby preventing targeting of the
mRNA transcript. Results showed a decrease in luciferase
activity of Suv39h1 S-3UTR relative to Suv39h1 AS-3UTR
in MVSMC transfected with a negative control hairpin for
the inhibitors (NC-I) derived from a C. elegans sequence
(Fig. 2E), most likely caused by endogenous miR-125b.
Moreover, this decrease was partially but signiﬁcantly
reversed by cotransfection with either miR-125b inhibitor
Inh.1 or Inh.2 (Fig. 2E) with no effect on the control
AS-3UTR. Thus, inhibition of miR-125b blocks the target-
ing of Suv39h1 3UTR, resulting in increased luciferase
activity. Together, these results further conﬁrm that
Suv39h1 3UTR is targeted by miR-125b.
miR-125b mimic downregulates endogenous Suv39h1.
We next examined whether transfection of miR-125b
mimic can induce a diabetic phenotype of decreased
Suv39h1 in control db/ MVSMC. Both Suv39h1 mRNA
levels (Fig. 3A) and protein levels (Fig. 3B) were
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db/db cells after transfection with the miR-125b relative
to NC-M.
We next tested whether, conversely, miR-125b-speciﬁc
inhibition can reverse the targeting of Suv39h1 and dia-
betic phenotype of db/db MVSMC. Transfection of db/db
MVSMC with miR-125b inhibitor hairpins Inh.1 or Inh.2, or
mixture of both, signiﬁcantly increased Suv39h1 mRNA
(Fig. 3C) and protein levels (Fig. 3D) compared with NC-I.
Neither the miR-125b mimic nor inhibitors had any effect
on glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
housekeeping gene levels in MVSMC (Fig. 3E–F) demon-
strating speciﬁcity. These results demonstrate that miR-
125b addition to normal cells can mimic, at least in part,
the diabetic phenotype by decreasing endogenous
Suv39h1, whereas, in contrast, miR-125b inhibitors reverse
these effects in diabetic cells.
miR-125b mediated knockdown of SUV39H1 leads to
decreased promoter H3K9me3 and increased inﬂam-
matory gene expression. We next evaluated whether
miR-125b mediated knockdown of Suv39h1 can func-
tionally decrease H3K9me3 at the promoters of inﬂam-
matory genes with a parallel increase in their
expression. HeLa cells were used here because of the
need for high transfection efﬁciency for the subsequent
assays. HeLa cells were transfected with miR-125b
mimic or NC-M, and processed for various assays 24 h
later. Immunoblotting of cell lysates conﬁrmed a signif-
icant decrease in endogenous human SUV39H1 protein
levels in cells transfected with miR-125b mimic relative
to NC-M (Fig. 4A and B) demonstrating that miR-125b
targeting of SUV39H1 can occur in multiple cell types.
ChIP assays showed that miR-125b mimic signiﬁcantly
decreased the repressive mark H3K9me3 at the IL-6 and
MCP-1 promoters and MCP-1 enhancer (Fig. 4C) and
reciprocally increased IL-6 and MCP-1 mRNA expres-
sion (Fig. 4D and E). The miR-125b mimic had no
signiﬁcant effect on H3K9me3 levels at the promoters of
housekeeping genes GAPDH or cyclophilin A (CYPA), or
on their expression levels (online supplemental Fig. S3A
and B) demonstrating speciﬁcity and that only a subset
of genes are regulated by Suv39h1. The speciﬁcity of
miR-125b was further evident from ChIP data showing
that miR-125b mimic did not affect either H3K9me1 or
H3K9me2 levels at the IL-6, MCP-1, CYPA and GAPDH
promoters, or MCP-1 enh in HeLa cells (online supple-
mental Fig. S4A and B). In addition,Western blots
showed that miR-125b mimic clearly decreased global
levels of only total H3K9me3, but not global H3K9me1 or
H3K9me2 (online supplemental Fig. S5).
To further verify the role of miR-125b targeting
SUV39H1 in leading to increased inﬂammatory gene
expression, we examined whether SUV39H1 overex-
pression can reverse the increased inﬂammatory gene
expression induced by exogenous miR-125b. HeLa cells
were cotransfected with miR-125b mimic or NC-M,
along with control empty vector pCR3.1 (pCR) or FLAG-
SUV39H1 (pSUV) expression vector, which does not
contain the SUV39H1 3UTR (i.e., no miR-125b seed
sequence). Cotransfection of miR-125b mimic with con-
trol pCR-induced inﬂammatory gene expression similar
to that seen in miR-125b mimic transfected cells (Fig. 4D
and E). However, miR-125b mimic-induced expression
of IL-6 and MCP-1 was clearly attenuated in pSUV
cotransfected cells relative to pCR (Fig. 4F). No signif-
icant changes were seen in CYPA expression (supple-
mental Fig. S3C) under these conditions. These results
further support the notion that decreased SUV39H1 and
promoter H3K9me3 are associated with a corresponding
upregulation of certain inﬂammatory genes similar to
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reversed by SUV39H1 reconstitution. This novel miR-
dependent regulation affects key disease related genes,
such as IL-6 and MCP-1, but not others tested, and can
be attenuated by blocking miR-125b.
miR-125b increases monocyte-MVSMC binding mim-
icking the diabetic phenotype. Monocyte recruitment
into the vessel wall plays a key role in atherosclerosis
(11,41). Monocyte adhesion to VSMC can increase sub-
endothelial monocyte retention, survival, and differen-
tiation, key steps in the progression of atherosclerosis
(42). Diabetic db/db MVSMC exhibit increased mono-
cyte binding relative to db/ controls, which can be
attributed to the increased expression of chemokines
such as MCP-1 (21). Therefore, we next examined the
functional relevance of our data by testing whether
increased miR-125b and the subsequent targeting of
Suv39h1 in the diabetic db/db MVSMC can increase
monocyte recruitment. We examined monocyte binding
to db/ MVSMC transfected with miR-125b mimic or
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transfected with NC-M. As seen in Fig. 5, miR-125b
mimic signiﬁcantly increased monocyte binding to db/
MVSMC relative to NC-M, and this was similar to that in
db/db cells transfected with NC-M (Fig. 5A–C and G). To
further verify the role of Suv39h1 and whether augment-
ing Suv39h1 expression can reverse the diabetic pheno-
type, we performed monocyte-VSMC binding assays
with db/db MVSMC transfected with FLAG-SUV39H1
lacking the 3UTR (pSUV) and control pCR3.1 (pCR).
Increasing SUV39H1 led to a small but signiﬁcant atten-
uation in monocyte binding to db/db MVSMC (Fig. 5D–F
and H). Although the increased monocyte binding in
miR-125b mimic transfected db/ MVSMC was not the
s a m ea si ndb/db MVSMC with NC-M, and reconstituting
SUV39H1 levels in db/db MVSMC only partially reversed
the diabetic phenotype of enhanced monocyte-MVSMC
adhesion, these changes were clearly signiﬁcant, dem-
onstrating that miR-125b plays a key, but not an exclu-
sive role, in diabetes-induced monocyte recruitment
into the vessel wall.
Increased transcriptional regulation of miR-125b in
db/db cells. We next examined potential regulatory mech-
anisms for miR-125b in db/db MVSMC. The mouse genome
has two copies of miR-125b, namely125b-1 and 125b-2,
with both processed into the same mature miR (http://
microrna.sanger.ac.uk/sequences) by enzymes such as
Drosha and Dicer (26–27). The miR-125b-1 is located in
the intron of a known protein coding transcript
(2610203C20Rik-201) within chromosome 9, whereas miR-
125b-2 is intergenic within chromosome 16 (Fig. 6A).
Primers ﬂanking the premiR-125b-1 sequence did not pick
up any transcripts (not shown), suggesting that it is
processed from the intron of 2610203C20Rik-201. Yet,
RT-qPCR to amplify 2610203C20Rik-201 itself (primers
p1-p2) indicated no change in its transcription in db/db
MVSMC relative to db/ (Fig. 6B, left two bars). On the
other hand, interestingly, RT-qPCR with primers ﬂanking
the premiR-125b-2 sequence (primers p3-p4) showed in-
creased transcription of miR-125b-2 in db/db cells relative
to db/ (Fig. 6B, right two bars).
We next veriﬁed the size of the miR-125b-2 transcript
ampliﬁed with primers p3-p4 using conventional PCR
followed by gel electrophoresis, and we detected a 240-
base pair (bp) unprocessed pri-miR-125b-2 which was
higher in db/db cells (Fig. 6C and D). Typically, pri-miRs
are thought to be short lived in the nucleus and rapidly
processed by Drosha into premiRs that are further pro-
cessed into mature miRs by Dicer (26–27). However, we
observed unprocessed pri-miR-125b-2 which was higher in
db/db cells, suggesting increased transcriptional regulation
of this region. Using the UCSC genome browser, we
identiﬁed two cDNAs (AK039756 and AK047945 RIKEN
full-length cDNA clones) that overlap with premiR-125b-2
(Fig. 6A right panel). RT-qPCR with primers p5-p6 de-
signed to detect both AK039756 and AK047945, but down-
stream of premiR-125b-2, also revealed a signiﬁcant
increase in transcription in this region in db/db MVSMC
relative to db/ (Fig. 6E).
We next performed PCRs with primers p3-p4 and p5-p6
to compare levels of the two transcripts. Both sets of
primers demonstrated an approximately twofold increase
in db/db MVSMC compared with db/ (Fig. 6F), but the
absolute amount of transcript was greater with the latter
set. These data suggest that miR-125b-2 may be tran-
scribed along with the RIKEN cDNAs and then processed
by Drosha and Dicer into the mature miR-125b. Since
primers p3-p4 amplify only the residual unprocessed (un-
cropped) portion of the pri-miRNA, the levels detected are
lower than the cDNA ampliﬁed with primers p5-p6 which
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which is not affected by Drosha processing. To further
verify these results, we performed RT-qPCR with primers
p3-p6 to amplify this longer fragment containing miR-
125b-2 along with the downstream sequence overlapping
the RIKEN cDNA clones. Since this longer fragment was
detectable (Fig. 6G), it likely constitutes a single transcript
and premiR-125b-2 is cropped from this primary tran-
script. Interestingly, this was again increased approxi-
mately twofold in db/db MVSMC (Fig. 6G), suggesting
increased transcription of any part of this region in db/db
cells. Overall these results suggest that elevated levels of
miR-125b are caused by increased transcriptional regula-
tion of miR-125b-2 (and not miR-125b-1) in db/db relative
to db/ MVSMC, and that miR-125b-2 may be processed
from the longer primary transcript containing either
AK039756 or AK047945 whose function is unknown to
date.
DISCUSSION
In this study, we uncovered a novel miR-dependent
mechanism for the epigenetic regulation of pathologic
genes in MVSMC of type 2 diabetic mice. There was
increased expression of miR-125b as well as key inﬂam-
matory genes in MVSMC derived from db/db mice rela-
tive to control db/ mice, and both these increases
persisted even after culturing the MVSMC for several
passages in vitro, possibly due to “metabolic memory” in
this type 2 diabetic mouse model. In addition, immuno-
blotting of cell lysates and immunohistochemistry of
aortic sections showed a decrease in Suv39h1 K9 HMT
in diabetic db/db mice relative to db/. We recently
showed that decreased Suv39h1 in db/db MVSMC can
play a role, at least in part, in the increased expression
of inﬂammatory genes in these cells (22). Interestingly,
we now found that Suv39h1 is a target of miR-125b, and
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H3K9me3 repressive marks at inﬂammatory gene pro-
moters, leading to a corresponding increase in expres-
sion of inﬂammatory genes such as IL-6 and MCP-1.T h e
miR-125b mimic speciﬁcally downregulated H3K9me3,
but not H3K9me2 and H3K9me1. Furthermore, increas-
ing miR-125b levels (with miR-125b mimic) in control
db/ MVSMC functionally led to increased monocyte-
MVSMC binding, mimicking the diabetic phenotype.
Since miR-125b could mimic key diabetic phenotypes,
aberrant regulation of miR-125b may be an underlying
mechanism for sustained vascular dysfunction, at least
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regulating a key chromatin HMT that normally keeps
key inﬂammatory genes in the repressed state (Fig. 7).
Additional histone modiﬁcations, such as H3K4-acetyla-
tion and H3K4me activating marks, as suggested in
previous studies (24–25,43), and/or key histone dem-
ethylases, may also cooperate to orchestrate dynamic
events at these gene promoters along with this miR-
mediated loss of repression to promote chronic vascular
inﬂammation and accelerated atherosclerosis seen in
diabetes (Fig. 7).
It has been reported that miR-125b targets p53 in
neuroblastoma and lung ﬁbroblast cells, effectively inhib-
iting apoptosis (44), whereas p53 was upregulated in
adipose tissue of type 2 diabetic mice and correlated with
increased oxidant stress, inﬂammation, and insulin resis-
tance (45). However, miR-125b levels in adipose tissue
were not evaluated. Additionally, a recent report in leuke-
mia cells did not identify p53 as a miR-125b target (46).
Thus, there may be cell-speciﬁc targeting of p53 by miR-
125b. It is unclear whether miR-125b plays a role in p53
regulation in diabetic VSMC. Although such p53-depen-
dent mechanisms could regulate the increased hypertro-
phy and proliferation of diabetic VSMC, they are beyond
the scope of this study.
In neural cells, miR-125b was upregulated by reactive
oxygen species (47), and via NF-B-dependent mecha-
nisms by TNF-	 in macrophages and human cholangiocyte
cells (48–49). Increased inﬂammatory genes in diabetes
and db/db vasculature have been attributed, at least in
part, to increased oxidant stress (50), which is also impli-
cated in metabolic memory and activation of the proin-
ﬂammatory transcription factor NF-B (3,6,17,24,51).
Thus, miR-125b might be regulated by oxidant stress and
proinﬂammatory stimuli under diabetic conditions, which
could target Suv39h1, leading to decreased H3K9me3 and
subsequent upregulation of inﬂammatory genes associated
with diabetic complications. This vicious cycle may ex-
plain the sustained expression of inﬂammatory genes in
diabetic db/db cells, even after in vitro culture where the
aberrant upregulation of miR-125b may contribute to
persistent vascular inﬂammation by targeting and sup-
pressing a crucial HMT which maintains key genes in a
controlled or repressed state.
Interestingly, high glucose could decrease inﬂammatory
gene promoter H3K9me3 in human VSMC and endothelial
cells (22,25), and increased expression of miR-125a (re-
lated to miR-125b) was observed in several tissues of GK
type 2 diabetic rats (52). However, it is not yet clear
whether high glucose can directly increase miR-125b or
decrease SUV39H1 protein levels. Other factors, including
altered Suv39h1 occupancy and/or H3K9 demethylases,
may also be involved in high glucose-induced decrease in
H3K9 methylation in VSMC. The mechanisms responsible
for the increased miR-125b in db/db MVSMC may be quite
complex, involving other factors related to type 2 diabetic
or insulin resistance in the db/db mice besides hypergly-
cemia. Additional work is needed to explore these aspects
and to determine whether miR-125b levels are reversed
after glycemic control in diabetic mice, and whether
miR-125b plays any role in metabolic memory.
The mechanisms by which miRs themselves are regu-
lated and expressed under normal or disease conditions
are currently of great interest. Our results suggest that the
increase in miR-125b is likely caused by increased tran-
scription of miR-125b-2. We identiﬁed two RIKEN cDNAs
partially overlapping with miR-125b-2, and RT-qPCR could
amplify a transcript covering this region. Our data indicate
that the cellular machinery may transcribe this region as
one transcript which then undergoes miR processing to
remove the 5end containing miR-125b-2 for majority of
the transcripts, whereas the remaining RIKEN cDNA clone
is more stable and maintains an as yet unknown function.
A potential promoter region for miR-125b-2 and the RIKEN
cDNAs was not easily identiﬁable based on sequence alone
and remains an interesting area of future research. In
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FIG. 7. Model for the mechanisms related to miR-125b mediated decrease in SUV39H1, leading to loss of repression of inﬂammation in diabetic
VSMC. Diabetic conditions in the db/db VSMC can promote the decrease of Suv39h1 (via increased miR-125b) and concomitant loss of repressive
chromatin marks such as H3K9 trimethylation (K9me3) relative to nondiabetic db cells. This can lead to a more open chromatin state (right)
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inﬂammatory genes. Various combinations of histone modiﬁcations are likely to be involved.
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copy of miR-125b cannot be ruled out. It is also not fully
clear how miR-125b or its promoter is regulated under
diabetic conditions, why it continues to remain elevated in
the diabetic cells even after culture in vitro, and if this
increase in miR-125b is caused by dysregulated chromatin
in the diabetic state or vice versa.
In summary, these results provide new insights into the
cross-talk and relationships between miRs and epigenetic
histone lysine methylation leading to inﬂammatory gene
expression in VSMC, especially in a disease relevant model
related to diabetic vascular inﬂammation. Although miR-
125b has been implicated in various cancers (28,53), this is
the ﬁrst indication of a role in vascular complications of
diabetes. Given the exciting advances in the development
of miR inhibitors, such as antagomirs and locked nucleic
acid modiﬁed small RNAs (54), anti-miR–based therapies
could potentially be developed for diabetic complications
and other inﬂammatory diseases.
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